[Perspectives of treatment of patients with ischemic stroke: the place and the role of cytoflavin].
Based on complex clinical-biochemical studies of 60 patients after ischemic stroke (on average 2,4+/-0,3 years from the disease-onset), we showed the disturbance of balance between anti- and prooxidant systems. The changes in the parameters of oxidative stress were revealed as follows: the reduction in the activity of antioxidant defense markers (superoxiddismutase, catalase, oxidized and reduced glutathione), as well as in the spontaneous and induced hemoluminescence, the increase of malonic dialdehyde, a final product of lipid peroxidation. The changes in biochemical parameters were correlated with the severity of ischemic stroke consequences, assessed by the Rankin scale and the Barthel index. This finding points out the necessity of including antioxidants in the rehabilitation treatment. The effect of antioxidant drugs on the consequences of ischemic stroke was studied using cytoflavin (10 ml in 200 ml of 5% glucose solution daily intravenous in drops during 10 days) and cortexin (10 mg in 2 ml of 5% novocaine solution daily intramuscular during 10 days). The results revealed a higher effect of cytoflavin that was supported by the data of clinical-biochemical blood analysis: the level of components of glutathione system and catalase was significantly (p<0,05) increased in patients with sensory-motor disturbances and cognitive disorders thought did not reach the levels of control group.
Trofimova
S A
SA
Balunov
O A
OA
Dubinina
E E
EE
D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
D000975:Antioxidants; D004338:Drug Combinations; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; C056590:cortexin; D007290:Inosine Diphosphate